Integra LifeSciences Cuts FY26 Guidance Following Cincinnati Facility Flooding; Stock Tumbles 11.4%
Integra LifeSciences (IART) cut its FY26 adjusted earnings and revenue guidance due to July flooding at its Cincinnati facility. Q3 adjusted earnings are expected between $0.55 and $0.59 per share on revenues of $410M-$412M. FY26 adjusted earnings are now projected at $2.30-$2.40 per share on revenues of $1.634B-$1.654B, down from previous guidance. The stock fell 11.44% in pre-market trading.
How this was made
The 30-second read
Why it matters
The guidance reduction and immediate price drop suggest heightened risk for investors; monitoring the facility's recovery timeline is key.
Market read
The news directly affects Integra's stock price and may influence sentiment toward similar med‑tech firms with concentrated manufacturing sites.
What to watch
Potential insurance recoveries or cost‑saving measures could mitigate the earnings hit.
Background
Integra LifeSciences reported unaudited Q3 numbers and revised FY26 guidance after a July flood at its Cincinnati facility disrupted production.
Ticker impact
Integra LifeSciences cut FY26 earnings and revenue guidance after flood damage, causing an 11.4% pre‑market drop.
downward pressure as investors price in reduced earnings and revenue outlook
The flood‑related supply disruption directly reduces revenue; the new guidance is materially lower than prior expectations, and the stock already fell 11% pre‑market.
Market effects
Medical device manufacturers may see heightened scrutiny of supply‑chain resilience.
U.S. healthcare sector could face modest downside pressure.
Limited to U.S. listed med‑tech stocks; no broader macro effect.
Counterpoint
If the flood impact is short‑lived, the stock may be oversold and could rebound on recovery news.
Key entities
- companyIntegra LifeSciences Holdings Corp.
Medical device manufacturer impacted by flood damage.
